Huma Therapeutics, a healthcare technology company that provides AI-powered digital health solutions and patient monitoring systems, has secured $80 million in series D funding to accelerate the adoption of digital tech solutions in healthcare and research.
Co-founded in 2011 by Dan Vahdat, and Rich Khatib, Huma has raised $300 million to date. The just-completed series D funding tranche included the participation of many investors, including AstraZeneca, Hitachi Ventures, and Hat Technology Fund 4 by HAT SGR.
The latest funding round will support the company’s growth and advancement of its newly launched Huma Cloud Platform, the first-ever Generative AI-powered ‘Shopify-like’ platform for the digital health ecosystem that will enable the design, development and launch of innovative health tech quickly.
Huma’s AI-powered Digital Health Cloud Platform
Built on a reputable global regulatory foundation approved by the US FDA and EU MDR, the Huma Cloud Platform provides a new-age alternative to traditional platforms that make the designing, developing, and launching of complaint digital health solutions slow.
The platform simplifies this complexity by providing a comprehensive suite of tools, such as pre-build modules, no-code configuration, cloud-agnostic framework, AI/ML hosting, API access, and a marketplace.
Huma’s technology powers muti-channel patient management healthcare systems, patient monitoring at scale, and companion apps to support patients through treatment and therapies.
Additionally, the platform supports multiple digital clinical trials and decentralized trials to support medical research. Currently, Huma’s platform serves more than 3000 hospitals and clinics, with 4 million registered users in healthcare.
Huma Therapeutics is known for its role in multi-national healthcare projects in the US, Germany, the UK, Saudi Arabia, and Greece. The company also collaborates with big pharma corporations.
